PLIANT THERAPEUTICS INC (PLRX)
US7291391057 - Common Stock
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader...
Oversold Conditions For Pliant Therapeutics (PLRX)
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE...
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to...
Pliant Therapeutics reports Q4 results (NASDAQ:PLRX)
Pliant Therapeutics reports Q4 expenses of $33.2M, net loss of $41.1M. Company has $495.7M in cash and is funded until H2 2026.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Pliant Therapeutics to Participate in Upcoming Investor Events
Commit To Buy Pliant Therapeutics At $12.50, Earn 11.5% Annualized Using Options
Pliant stock gains on new data for lead asset (NASDAQ:PLRX)
Pliant Therapeutics (PLRX) updated results from a mid-stage trial for its lead asset bexotegrast in primary sclerosing cholangitis (PSC). Read more here.
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns...
PLRX Makes Bullish Cross Above Critical Moving Average
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D.,...
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation...
Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08 (NASDAQ:PLRX)
Pliant Therapeutics reported a Q3 GAAP EPS of -$0.70, beating expectations by $0.08.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Commit To Buy Pliant Therapeutics At $10, Earn 14% Using Options
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and...
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13...
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and...